$PHIO News

Last published 6d ago

6d agoPHIOPhio Pharmaceuticals Corp. - EXHIBIT 99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
3mo agoPHIOEarnings Call - PHIO PHARMACEUTICALS CORPEarnings Call Transcriptsbiopharmaceuticals is a clinical stage biopharma company which has recently completed a successful phase 1b clinical trial focused on the treatment of skin cancers phyo utilizes its proprietary technology called intasil
7mo agoPHIOForce Webinar: Phio Pharmaceutical, 15 April 2026 - PHIO PHARMACEUTICALS CORPEarnings Call TranscriptsHi, everyone. Thank you so much for joining us today. Before we kick this off, I do want to point out to the audience that we welcome questions. Please post them in the Q&A section at the bottom of your screen. Type them
8mo agoPHIOPhio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026 11 AM EDTGlobeNewswireThe Company invites individual and institutional investors, as well as advisors and analysts with an interest in the life sciences sector, to attend live, interactive presentations at VirtualInvestorConferences.com KING
2y agoPHIOPhio Pharmaceuticals Secures New InvestorGlobeNewswireMARLBOROUGH, Mass., May 17, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to
2y agoPHIOPhio Pharmaceuticals Presents This Week at the Society for Investigative Dermatology (SID)GlobeNewswireMARLBOROUGH, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to
2y agoPHIOPhio Pharmaceuticals Announces Completion of Dosing in First Patient Cohort in PH-762 Phase 1b Dose-Escalation StudyGlobeNewswire-PH-762 is Phio's lead product candidate -Screening on the next cohort is on-going MARLBOROUGH, Mass., May 15, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical stage biotechnology company
2y agoPHIOPhio Pharmaceuticals Reports Q1 2024 Results and Provides Business UpdateGlobeNewswire–Four sites across the country participating in Phase 1b clinical trial for lead product candidate PH-762 –Three patients have been enrolled MARLBOROUGH, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals
2y agoPHIOPhio Pharmaceuticals Announces Upcoming Presentation at the Annual Meeting of the Society of Clinical Oncology (ASCO)GlobeNewswireMARLBOROUGH, Mass., April 30, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to
2y agoPHIOIntratumoral Injection of Phio's PH-762 significantly inhibits tumor growth in murine tumor models and may generate memory-specific T cellsGlobeNewswire-Injection in murine tumors shows the compound is well tolerated -Studies support ongoing clinical trial of PH-762 as a neoadjuvant therapy for treatment of cSCC, melanoma, or Merkel cell carcinoma MARLBOROUGH, Mass.,
2y agoPHIOPhio Pharmaceuticals Announces Upcoming Presentations at the 81st Annual Meeting of the Society for Investigative Dermatology (SID)GlobeNewswireMARLBOROUGH, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to
2y agoPHIOPhio Pharmaceuticals Announces Upcoming Presentation at the 27th Annual Meeting of the American Society of Cell and Gene Therapy (ASCGT)GlobeNewswireMARLBOROUGH, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to
2y agoPHIONational Spotlight Features Phio's Innovative RNAi Technology PlatformGlobeNewswire—Program will be airing on PBS with Dennis Quaid in April —It will also be seen on Fox Business Network MARLBOROUGH, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical
2y agoPHIOPhio Pharmaceuticals Reports 2023 Year End Financial Results and Provides Business UpdateGlobeNewswire– Four sites across the country participating in clinical trial for lead product candidate PH-762 – Two patients have already completed treatment – New patent granted for skin related treatments, extending Phio's
2y agoPHIOPhio Pharmaceuticals Presenting Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological MalignanciesGlobeNewswireMARLBOROUGH, Mass., March 21, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to
2y agoPHIOPhio Pharmaceuticals Announces Addition of Clinical Trial Sites at Banner MD Anderson Cancer Center, The George Washington University, and Integrity ResearchGlobeNewswireMARLBOROUGH, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to
2y agoPHIOPhio Pharmaceuticals Announces Patent Granted by USPTO, Strengthening the Company's Intellectual Property Position in Treating Aging Skin and Skin DisordersGlobeNewswireMARLBOROUGH, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to
2y agoPHIOPhio Pharmaceuticals Announces Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological MalignanciesGlobeNewswire--New preclinical data to be presented at Immunotherapy Conference in Germany MARLBOROUGH, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical stage biotechnology company
2y agoPHIOPhio Pharmaceuticals Announces Exercise of Warrants for $2.8 Million Gross ProceedsGlobeNewswireMARLBOROUGH, Mass., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make
3y agoPHIOPhio Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business UpdateGlobeNewswireMARLBOROUGH, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make
3y agoPHIOPhio Pharmaceuticals Announces First US Patient Enrolled in Phase 1B Clinical Trial with Intratumoral PH-762 anti-PD-1 Therapy for Treatment of Skin CarcinomasGlobeNewswireMARLBOROUGH, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make
3y agoPHIOPhio Pharmaceuticals Presents New Data Showing INTASYL Compound targeting CTLA-4 Enhances Tumor ControlGlobeNewswireMARLBOROUGH, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make
3y agoPHIOPhio Pharmaceuticals Announces Upcoming Presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)GlobeNewswireMARLBOROUGH, Mass., Oct. 12, 2023 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make
3y agoPHIOPhio Pharmaceuticals Presents New Data for Targeting of BRD4 with its INTASYL™ Compound PH-894GlobeNewswire--Preclinical data shows melanoma cells treated with PH-894 makes them more recognizable to immune cells, increasing potential for elimination --Preclinical data demonstrates the effectiveness of PH-894 as an antitumor
3y agoPHIOPhio CEO to Speak at Wainwright Conference in New York in SeptemberGlobeNewswireMARLBOROUGH, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals (NASDAQ:PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune
3y agoPHIOPhio Pharmaceuticals Announces Dosing of First Patient in Collaborative Clinical Trial with AgonOx, Inc. and Providence Cancer InstituteGlobeNewswireMARLBOROUGH, Mass., Aug. 21, 2023 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make
3y agoPHIOPhio Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business UpdateGlobeNewswireMARLBOROUGH, Mass., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make
3y agoPHIOPhio Pharmaceuticals Announces Closing of $4 Million Concurrent Registered Direct Offering and Private Placement Priced At-the-Market Under Nasdaq RulesPR NewswireMARLBOROUGH, Mass., June 2, 2023 /PRNewswire/ -- Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune
3y agoPHIOPhio Pharmaceuticals Announces $4 Million Concurrent Registered Direct Offering and Private Placement Priced At-the-Market Under Nasdaq RulesPR NewswireMARLBOROUGH, Mass., May 31, 2023 /PRNewswire/ -- Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune
3y agoPHIOPhio Pharmaceuticals Announces Initiation of Collaborative Clinical Trial with PH-762, AgonOx's Tumor Infiltrating Lymphocyte Program (AGX148) and Providence Cancer InstitutePR NewswireOne of two newly announced clinical trials for its lead product candidate, PH-762 MARLBOROUGH, Mass., May 24, 2023 /PRNewswire/ -- Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical stage biotechnology company whose
3y agoPHIOPhio Pharmaceuticals Presents Preclinical Study Showing INTASYL™ Treatment of NK Cells More than Doubles Ability to Kill Tumor CellsPR NewswireData is being presented at 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting MARLBOROUGH, Mass., May 18, 2023 /PRNewswire/ -- Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical stage biotechnology
3y agoPHIOPhio Pharmaceuticals Announces FDA Clearance to Initiate Clinical Trial of PH-762 for Treatment of Skin CarcinomasPR NewswireMARLBOROUGH, Mass., May 16, 2023 /PRNewswire/ -- Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune
3y agoPHIOPhio Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business UpdatePR NewswireMARLBOROUGH, Mass., May 11, 2023 /PRNewswire/ -- Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune
3y agoPHIOPhio Pharmaceuticals Announces Closing of $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesPR NewswireMARLBOROUGH, Mass., April 20, 2023 /PRNewswire/ -- Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune
3y agoPHIOPhio Pharmaceuticals Presents Preclinical Data Demonstrating Synergy-Enhanced in vivo Anti-Tumor Efficacy of PD-1/CTLA-4 Dual-Targeting INTASYLPR Newswire- Data to be presented at American Association for Cancer Research (AACR) Annual Meeting 2023 - MARLBOROUGH, Mass., April 18, 2023 /PRNewswire/ -- Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical stage biotechnology
3y agoPHIOPhio Pharmaceuticals Presents Preclinical Study Showing PH-762 Induces Systemic Memory T Cell Mediators of Anti-Tumor ImmunityPR Newswire- Data to be presented at American Association for Cancer Research (AACR) Annual Meeting 2023 - MARLBOROUGH, Mass., April 17, 2023 /PRNewswire/ -- Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical stage biotechnology
3y agoPHIOPhio Pharmaceuticals Reports 2022 Year End Financial Results and Provides Business UpdatePR Newswire– Following safety data review by the DMC, enrollment is now open for the second cohort of its Phase 1b study of PH-762 for the treatment of advanced melanoma – – Received confirmation from the FDA that the planned Phase
3y agoPHIOPhio Pharmaceuticals Appoints Robert Bitterman as President and Chief Executive OfficerPR NewswireMARLBOROUGH, Mass., Feb. 22, 2023 /PRNewswire/ -- Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune
3y agoPHIOPhio Pharmaceuticals Regains Compliance with Nasdaq Listing RequirementsPR NewswireMARLBOROUGH, Mass., Feb. 13, 2023 /PRNewswire/ -- Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune
3y agoPHIOPhio Pharmaceuticals Announces Positive DMC Recommendation and Continued Enrollment of Advanced Melanoma Study Without ModificationPR NewswireMARLBOROUGH, Mass., Feb. 10, 2023 /PRNewswire/ -- Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune
3y agoPHIOPhio Pharmaceuticals Announces Reverse Stock SplitPR NewswireMARLBOROUGH, Mass., Jan. 25, 2023 /PRNewswire/ -- Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune
3y agoPHIOPhio Showcases Innovations in Dermatology Cancers at 2023 Dermatology Summit in San FranciscoPR NewswireMARLBOROUGH, Mass., Jan. 6, 2023 /PRNewswire/ -- Phio Pharmaceuticals (NASDAQ:PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more
3y agoPHIOPhio Pharmaceuticals Announces Regulatory Clearance of Clinical Trial With PH-762 and AgonOx's Tumor Infiltrating Lymphocytes (AGX148) to Treat Solid TumorsPR NewswireMARLBOROUGH, Mass., Jan. 6, 2023 /PRNewswire/ -- Phio Pharmaceuticals Corp. (NASDAQ:PHIO) today announced their clinical development partner, AgonOx, Inc. has received confirmation from the FDA that their planned Phase 1
3y agoPHIOPhio Pharmaceuticals Announces New Clinical Program to Study PH-762 for the Treatment of Cutaneous Squamous Cell CarcinomaPR NewswireMARLBOROUGH, Mass., Dec. 21, 2022 /PRNewswire/ -- Phio Pharmaceuticals Corp., today announced it expects to file an IND in the US in the first half of 2023 for a Phase 1b clinical trial of its INTASYL™ compound,
4y agoPHIOPhio Announces New Appointments to Leadership Team, Reports on Third Quarter 2022 Financial Results and Provides Business UpdatePR NewswireNew executive team leading development of Phio's RNAi compounds and proprietary INTASYL™ platform Continuing enrollment in its Phase 1b study of PH-762 for the treatment of advanced melanoma Additional studies
4y agoPHIOPhio Pharmaceuticals Announces Study Results at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on November 10th and 11thPR NewswirePhio's INTASYL™ compounds demonstrated activity against multiple protein targets including PD-1, BRD4, CTLA-4, TIGIT and CTGF. INTASYL™ compounds demonstrated preclinical activity in both
4y agoPHIOPhio Pharmaceuticals Announces Appointment of Robert Bitterman as Executive ChairmanPR NewswireMARLBOROUGH, Mass., Sept. 29, 2022 /PRNewswire/ -- Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic pl
4y agoPHIOPhio Pharmaceuticals Announces Preclinical Data Demonstrating PH-762 Enhances Persistence of T cells for Tumor Cell Killing as Presented by Helmholtz Munich at the 9th Immunotherapy of Cancer ConferencePR NewswireMARLBOROUGH, Mass., Sept. 22, 2022 /PRNewswire/ -- Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic plat
4y agoPHIOPhio Pharmaceuticals Announces Acceptance of Six Abstracts at The 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)PR NewswireMARLBOROUGH, Mass., Sept. 12, 2022 /PRNewswire/ -- Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic plat
4y agoPHIOPhio Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business UpdatePR NewswireInitiated dosing of subjects and enrollment ongoing in the first-in-human clinical study of PH-762 for the treatment of advanced melanoma; expect to announce top-line data from the first group of subjects in Q1 2023 Expects to initiate a clinical trial